Alimera Sciences, Inc. · Alpharetta, GA United States (NASDAQ: ALIM)
| 6120 Windward Pkwy., Ste. 290 | Phone: 678-990-5740 |
| Alpharetta, GA | Fax: 678-990-5744 |
| 30005 | |
| United States | 
Map This Company |
Alimera Sciences, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Alimera Sciences wants to see clear into the future. The biopharmaceutical company is developing prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert, smaller than a grain of rice, that slowly releases a corticosteroid to the back of the eye to treat diabetic macular edema (DME). DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. The company had hoped to gain
Alimera Sciences, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ALIM Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 27 |
Executives
19 executives listed for Alimera Sciences, Inc.'s Alpharetta, GA location.
| Chairman | Philip Tracy | |
|---|---|---|
| President, CEO, and Director | C. Daniel Myers | |
| COO and CFO | Richard Eiswirth |